Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 43

1.

Small Heterodimer Partner regulates dichotomous T cell expansion by macrophages.

Shahoei SH, Kim YC, Cler SJ, Ma L, Anakk S, Kemper JK, Nelson ER.

Endocrinology. 2019 May 3. pii: en.2019-00025. doi: 10.1210/en.2019-00025. [Epub ahead of print]

PMID:
31050726
2.

Host CYP27A1 expression is essential for ovarian cancer progression.

He S, Ma L, Baek AE, Vardanyan A, Vembar V, Chen JJ, Nelson AT, Burdette JE, Nelson ER.

Endocr Relat Cancer. 2019 May 1. pii: ERC-18-0572.R1. doi: 10.1530/ERC-18-0572. [Epub ahead of print]

PMID:
31048561
3.

Nuclear receptors, cholesterol homeostasis and the immune system.

Shahoei SH, Nelson ER.

J Steroid Biochem Mol Biol. 2019 Apr 16;191:105364. doi: 10.1016/j.jsbmb.2019.04.013. [Epub ahead of print] Review.

PMID:
31002862
4.

Oxysterols and nuclear receptors.

Ma L, Nelson ER.

Mol Cell Endocrinol. 2019 Mar 15;484:42-51. doi: 10.1016/j.mce.2019.01.016. Epub 2019 Jan 18. Review.

PMID:
30660701
5.

Estrogen-independent Myc overexpression confers endocrine therapy resistance on breast cancer cells expressing ERαY537S and ERαD538G mutations.

Yu L, Wang L, Mao C, Duraki D, Kim JE, Huang R, Helferich WG, Nelson ER, Park BH, Shapiro DJ.

Cancer Lett. 2019 Feb 1;442:373-382. doi: 10.1016/j.canlet.2018.10.041. Epub 2018 Nov 9.

PMID:
30419347
6.

The cholesterol metabolite 27 hydroxycholesterol facilitates breast cancer metastasis through its actions on immune cells.

Baek AE, Yu YA, He S, Wardell SE, Chang CY, Kwon S, Pillai RV, McDowell HB, Thompson JW, Dubois LG, Sullivan PM, Kemper JK, Gunn MD, McDonnell DP, Nelson ER.

Nat Commun. 2017 Oct 11;8(1):864. doi: 10.1038/s41467-017-00910-z.

7.

27-Hydroxycholesterol, an endogenous selective estrogen receptor modulator.

He S, Nelson ER.

Maturitas. 2017 Oct;104:29-35. doi: 10.1016/j.maturitas.2017.07.014. Epub 2017 Jul 31. Review.

8.

The significance of cholesterol and its metabolite, 27-hydroxycholesterol in breast cancer.

Nelson ER.

Mol Cell Endocrinol. 2018 May 5;466:73-80. doi: 10.1016/j.mce.2017.09.021. Epub 2017 Sep 15. Review.

9.

CYP27A1 Loss Dysregulates Cholesterol Homeostasis in Prostate Cancer.

Alfaqih MA, Nelson ER, Liu W, Safi R, Jasper JS, Macias E, Geradts J, Thompson JW, Dubois LG, Freeman MR, Chang CY, Chi JT, McDonnell DP, Freedland SJ.

Cancer Res. 2017 Apr 1;77(7):1662-1673. doi: 10.1158/0008-5472.CAN-16-2738. Epub 2017 Jan 27.

10.

Chemotherapy enriches for an invasive triple-negative breast tumor cell subpopulation expressing a precursor form of N-cadherin on the cell surface.

Nelson ER, Li S, Kennedy M, Payne S, Kilibarda K, Groth J, Bowie M, Parilla-Castellar E, de Ridder G, Marcom PK, Lyes M, Peterson BL, Cook M, Pizzo SV, McDonnell DP, Bachelder RE.

Oncotarget. 2016 Dec 20;7(51):84030-84042. doi: 10.18632/oncotarget.12767.

11.

Thyroid hormone regulates vitellogenin by inducing estrogen receptor alpha in the goldfish liver.

Nelson ER, Habibi HR.

Mol Cell Endocrinol. 2016 Nov 15;436:259-67. doi: 10.1016/j.mce.2016.08.045. Epub 2016 Aug 30.

PMID:
27585488
12.

Targeting multidrug-resistant ovarian cancer through estrogen receptor α dependent ATP depletion caused by hyperactivation of the unfolded protein response.

Zheng X, Andruska N, Lambrecht MJ, He S, Parissenti A, Hergenrother PJ, Nelson ER, Shapiro DJ.

Oncotarget. 2016 Jul 24;9(19):14741-14753. doi: 10.18632/oncotarget.10819. eCollection 2018 Mar 13.

13.

Efficient Targeting of Adipose Tissue Macrophages in Obesity with Polysaccharide Nanocarriers.

Ma L, Liu TW, Wallig MA, Dobrucki IT, Dobrucki LW, Nelson ER, Swanson KS, Smith AM.

ACS Nano. 2016 Jul 26;10(7):6952-62. doi: 10.1021/acsnano.6b02878. Epub 2016 Jun 23.

PMID:
27281538
14.

The Contribution of Cholesterol and Its Metabolites to the Pathophysiology of Breast Cancer.

Baek AE, Nelson ER.

Horm Cancer. 2016 Aug;7(4):219-28. doi: 10.1007/s12672-016-0262-5. Epub 2016 Mar 28. Review.

15.

A Protocol for the Comprehensive Flow Cytometric Analysis of Immune Cells in Normal and Inflamed Murine Non-Lymphoid Tissues.

Yu YR, O'Koren EG, Hotten DF, Kan MJ, Kopin D, Nelson ER, Que L, Gunn MD.

PLoS One. 2016 Mar 3;11(3):e0150606. doi: 10.1371/journal.pone.0150606. eCollection 2016.

16.

Detection of Endogenous Selective Estrogen Receptor Modulators such as 27-Hydroxycholesterol.

Nelson ER.

Methods Mol Biol. 2016;1366:431-443. doi: 10.1007/978-1-4939-3127-9_34.

PMID:
26585155
17.

Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader.

Wardell SE, Nelson ER, Chao CA, Alley HM, McDonnell DP.

Endocr Relat Cancer. 2015 Oct;22(5):713-24. doi: 10.1530/ERC-15-0287. Epub 2015 Jul 10.

18.

Cholesterol and breast cancer pathophysiology.

Nelson ER, Chang CY, McDonnell DP.

Trends Endocrinol Metab. 2014 Dec;25(12):649-55. doi: 10.1016/j.tem.2014.10.001. Epub 2014 Nov 4. Review.

19.

Copper signaling axis as a target for prostate cancer therapeutics.

Safi R, Nelson ER, Chitneni SK, Franz KJ, George DJ, Zalutsky MR, McDonnell DP.

Cancer Res. 2014 Oct 15;74(20):5819-31. doi: 10.1158/0008-5472.CAN-13-3527.

20.

Delineation of a FOXA1/ERα/AGR2 regulatory loop that is dysregulated in endocrine therapy-resistant breast cancer.

Wright TM, Wardell SE, Jasper JS, Stice JP, Safi R, Nelson ER, McDonnell DP.

Mol Cancer Res. 2014 Dec;12(12):1829-39. doi: 10.1158/1541-7786.MCR-14-0195. Epub 2014 Aug 6.

Supplemental Content

Loading ...
Support Center